Carmignac Gestion Merus N.V. Transaction History

Carmignac Gestion

$5.85 Billion
Q1 2025

A detailed history of Carmignac Gestion transactions in Merus N.V. stock. As of the latest transaction made, Carmignac Gestion holds 121,161 shares of MRUS stock, worth $6.06 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

121,161

Holding current value

$6.06 Million

% of portfolio

0.09%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$39.01 - $49.16 $4.73 Million - $5.96 Million	121,161 New	121,161 $5.1 Million
Q2 2024 Aug 13, 2024	BUY	$39.81 - $60.2 $123,649 - $186,981	3,106 Added 7.93%	42,278 $2.5 Million
Q1 2024 May 14, 2024	SELL	$28.03 - $51.82 $10.2 Million - $18.9 Million	-364,689 Reduced 90.3%	39,172 $1.76 Million
Q4 2023 Feb 13, 2024	SELL	$20.06 - $28.66 $1.01 Million - $1.45 Million	-50,470 Reduced 11.11%	403,861 $11.1 Million
Q3 2023 Nov 13, 2023	BUY	$20.13 - $27.29 $805,361 - $1.09 Million	40,008 Added 9.66%	454,331 $10.7 Million
Q2 2023 Aug 11, 2023	SELL	$18.33 - $27.18 $1.11 Million - $1.64 Million	-60,329 Reduced 12.71%	414,323 $10.9 Million
Q1 2023 May 12, 2023	BUY	$14.25 - $20.5 $356,250 - $512,500	25,000 Added 5.56%	474,652 $8.73 Million
Q4 2022 Feb 13, 2023	BUY	$12.8 - $23.66 $5.76 Million - $10.6 Million	449,652 New	449,652 $6.96 Million

Others Institutions Holding MRUS

# of Institutions

195

Shares Held

62.2M

Call Options Held

355K

Put Options Held

96.5K

Wellington Management Group LLP Boston, MA

4.72M
Shares

$236 Million
0.04% of portfolio
Commodore Capital LP New York, NY

4.47M
Shares

$224 Million
18.43% of portfolio
Rtw Investments, LP New York, NY

4.17M
Shares

$209 Million
2.88% of portfolio
Paradigm Biocapital Advisors LP New York, NY

3.37M
Shares

$169 Million
7.27% of portfolio
Deerfield Management Company, L.P. (Series C) New York, NY

3.17M
Shares

$159 Million
3.38% of portfolio

View Full List

About Merus N.V.

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $2.29B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

More about MRUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Carmignac Gestion, based on Form 13F filings with the SEC.

News

Stay updated on Carmignac Gestion with notifications on news.

Account